About
A wire service for peptide medicine
Peptide Zone files short, structured news about medicines built from peptides: GLP-1 and amylin drugs, peptide hormones and their analogues, peptide vaccines and the unapproved compounds sold around them.
Last updated
What the wire covers
Four kinds of event make the wire: a regulator acts, a trial reports, the industry moves, or a safety question comes up. Each has its own desk with a three-letter code, and a fifth desk holds the explainers that give the news its background. The 39 stories on the wire today are listed in filing order on the full wire.
Every story opens with a slugline and a dateline, names one key number, answers three questions (what is new, why it matters, what comes next) and ends with its primary source. Stories that belong to a longer storyline join a thread, so a reader can follow one subject across months.
How stories are filed
Peptide Zone is run by a small independent team. Stories appear under the wire's name rather than a personal byline. Events are gathered from public news feeds, agency pages and journals; drafts are prepared with AI assistance from the documents a story cites, checked by automated tests and filed by an editor. The full process, including how errors are corrected, is on the standards page.
What you will not find here
- Advertising, sponsored stories, affiliate links or shop listings.
- Doses, protocols or places to buy peptides.
- Personal medical advice. The disclaimer explains why.
Reach the newsroom
Corrections, tips about public documents and questions about a story go through the contact form. We read every message; we cannot answer questions about individual treatment.